SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Laboratory Corp. of America Holdings – ‘10-K’ for 12/31/20 – ‘EX-24.7’

On:  Thursday, 2/25/21, at 3:19pm ET   ·   For:  12/31/20   ·   Accession #:  920148-21-18   ·   File #:  1-11353

Previous ‘10-K’:  ‘10-K/A’ on 3/5/20 for 12/31/19   ·   Next:  ‘10-K’ on 2/25/22 for 12/31/21   ·   Latest:  ‘10-K’ on 2/26/24 for 12/31/23   ·   28 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/25/21  Lab Corp. of America Holdings     10-K       12/31/20  116:19M

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.05M 
 2: EX-4.16     Instrument Defining the Rights of Security Holders  HTML     37K 
 3: EX-10.21    Material Contract                                   HTML    112K 
 4: EX-21       Subsidiaries List                                   HTML     53K 
 5: EX-23.1     Consent of Expert or Counsel                        HTML     28K 
 6: EX-24.1     Power of Attorney                                   HTML     30K 
 7: EX-24.2     Power of Attorney                                   HTML     30K 
 8: EX-24.3     Power of Attorney                                   HTML     30K 
 9: EX-24.4     Power of Attorney                                   HTML     30K 
10: EX-24.5     Power of Attorney                                   HTML     30K 
11: EX-24.6     Power of Attorney                                   HTML     30K 
12: EX-24.7     Power of Attorney                                   HTML     30K 
13: EX-24.8     Power of Attorney                                   HTML     30K 
14: EX-31.1     Certification -- §302 - SOA'02                      HTML     33K 
15: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
16: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
23: R1          Document and Entity Information Document            HTML     92K 
24: R2          Consolidated Balance Sheets                         HTML    141K 
25: R3          Consolidated Statements of Operations               HTML     89K 
26: R4          Consolidated Statements of Cash Flows               HTML    131K 
27: R5          Other Liabilities                                   HTML     37K 
28: R6          Other Liabilities                                   HTML     36K 
29: R7          Other Liabilities                                   HTML     34K 
30: R8          Consolidated Balance Sheet (Parentheticals)         HTML     30K 
31: R9          Consolidated Statements of Comprehensive Earnings   HTML     66K 
32: R10         Consolidated Statements of Changes in               HTML     92K 
                Shareholders' Equity                                             
33: R11         Restructuring and Other Charges                     HTML     70K 
34: R12         Supplemental Cash Flow Information                  HTML     44K 
35: R13         Supplemental Cash Flow Information                  HTML     43K 
36: R14         Summary of Significant Accounting - Net Sales       HTML     39K 
37: R15         Restructuring and Other Charges                     HTML     50K 
38: R16         Supplemental Cash Flow Information                  HTML     43K 
39: R17         Organization, Consolidation and Presentation of     HTML    113K 
                Financial Statements                                             
40: R18         Business Acquisitions                               HTML     85K 
41: R19         Restructuring Liabilities                           HTML     70K 
42: R20         Joint Venture Partnerships and Equity Method        HTML     40K 
                Investments                                                      
43: R21         Accounts Receivable, Net                            HTML     45K 
44: R22         Property, Plant and Equipment, Net                  HTML     43K 
45: R23         Goodwill and Intangible Assets                      HTML     85K 
46: R24         Accrued Expenses and Other                          HTML     37K 
47: R25         Debt                                                HTML     70K 
48: R26         Preferred Stock and Common Shareholders' Equity     HTML     69K 
49: R27         Income Taxes                                        HTML    124K 
50: R28         Stock Compensation Plans                            HTML     98K 
51: R29         Leases (Notes)                                      HTML     82K 
52: R30         Commitments and Contingent Liabilities              HTML     70K 
53: R31         Pension and Postretirement Plans (Note)             HTML    253K 
54: R32         Fair Value Measurements                             HTML     84K 
55: R33         Derivative Instruments and Hedging Activities       HTML     65K 
56: R34         Business Segments [Disclosure] Business Segment     HTML     93K 
                (Notes)                                                          
57: R35         Summary of Significant Accounting Policies          HTML    169K 
58: R36         REVENUE Segment Revenue Recognition (Policies)      HTML    149K 
59: R37         Summary of Significant Accounting Policies          HTML     72K 
                (Tables)                                                         
60: R38         BUSINESS ACQUISITIONS & DISPOSITIONS Business       HTML     74K 
                Acquisitions (Tables)                                            
61: R39         Restructuring Reserves (Tables)                     HTML     68K 
62: R40         Joint Venture Partnerships and Equity Method        HTML     38K 
                Investments (Tables)                                             
63: R41         Accounts Receivable, Net (Tables)                   HTML     36K 
64: R42         Property, Plant and Equipment, Net (Tables)         HTML     42K 
65: R43         Goodwill and Intangible Assets (Tables)             HTML     88K 
66: R44         Accrued Expenses and Other (Tables)                 HTML     37K 
67: R45         Debt (Tables)                                       HTML     86K 
68: R46         Preferred Stock and Common Shareholders' Equity     HTML     75K 
                (Tables)                                                         
69: R47         Income Taxes (Tables)                               HTML    128K 
70: R48         Stock Compensation Plans (Tables)                   HTML     80K 
71: R49         Leases (Tables)                                     HTML    117K 
72: R50         PENSION AND POSTRETIREMENT PLANS Pension and        HTML    200K 
                Postretirement Plans (Tables)                                    
73: R51         Fair Value Measurements (Tables)                    HTML     64K 
74: R52         Derivative Instruments and Hedging Activities       HTML     65K 
                (Tables)                                                         
75: R53         Business Segments [Disclosure] Schedule of Segment  HTML     89K 
                Reporting Information (Tables)                                   
76: R54         Revenue (Tables)                                    HTML    126K 
77: R55         Summary of Significant Accounting Policies          HTML     57K 
78: R56         Summary of Significant Accounting - Earnings Per    HTML     67K 
                Share                                                            
79: R57         Summary of Significant Accounting - Property,       HTML     50K 
                Plant and Equipment                                              
80: R58         Summary of Significant Accounting - Intangible      HTML     49K 
                Assets                                                           
81: R59         Summary of Significant Accounting Policies -        HTML     54K 
                Covid-19                                                         
82: R60         Business Acquisitions (Details)                     HTML    156K 
83: R61         Business Acquisitions & Dispositions Dispositions   HTML    108K 
                (Details)                                                        
84: R62         BUSINESS ACQUISITIONS & DISPOSITIONS Envigo         HTML    103K 
                (Details)                                                        
85: R63         Restructuring Reserves (Details)                    HTML     71K 
86: R64         Joint Venture Partnerships and Equity Method        HTML     46K 
                Investments (Details)                                            
87: R65         Accounts Receivable, Net (Details)                  HTML     44K 
88: R66         Property, Plant and Equipment, Net (Details)        HTML     64K 
89: R67         Goodwill and Intangible Assets (Details)            HTML     70K 
90: R68         Goodwill and Intangible Assets - Schedule of        HTML     53K 
                Goodwill (Details)                                               
91: R69         Goodwill and Intangible Assets - Components of      HTML     66K 
                Identifiable Intangible Assets (Details)                         
92: R70         Goodwill and Intangible Assets - Summary of         HTML     41K 
                Acquired Amortizable Intangible Assets (Details)                 
93: R71         Accrued Expenses and Other (Details)                HTML     38K 
94: R72         Debt - Schedule of Short-Term Debt (Details)        HTML     40K 
95: R73         Debt - Schedule of Long-Term Debt (Details)         HTML     90K 
96: R74         Debt - Credit Facilities (Details)                  HTML    112K 
97: R75         Debt - Covertible Subordinated Notes (Details)      HTML     70K 
98: R76         Debt - Senior Notes (Details)                       HTML     79K 
99: R77         Preferred Stock and Common Shareholders' Equity     HTML    124K 
                (Details)                                                        
100: R78         Income Taxes (Details)                              HTML    212K  
101: R79         Stock Compensation Plans (Details)                  HTML    133K  
102: R80         Leases (Details)                                    HTML    158K  
103: R81         Pension and Postretirement Plans (Details)          HTML    286K  
104: R82         Defined Benefit Plans, Fair Value of Plan Assets    HTML    176K  
                (Details)                                                        
105: R83         Pension and Postretirement Plans, Other             HTML     93K  
                Disclosures (Details)                                            
106: R84         Pension and Postretirement Plans Pension and        HTML     35K  
                Postretirement Plans, Funded Status (Details)                    
107: R85         Fair Value Measurements (Details)                   HTML     72K  
108: R86         Derivative Instruments and Hedging Activities       HTML     86K  
                (Schedule of Derivative Instruments in Statement                 
                of Financial Position at Fair Value) (Details)                   
109: R87         Derivative Instruments and Hedging Activities       HTML     62K  
                (Effects of Interest Rate Swap on Other                          
                Comprehensive Income) (Details)                                  
110: R88         Business Segments [Disclosure] (Details)            HTML    111K  
111: R89         Revenue (Details)                                   HTML    276K  
112: R9999       Uncategorized Items - lh-20201231.htm               HTML     40K  
114: XML         IDEA XML File -- Filing Summary                      XML    198K  
22: XML         XBRL Instance -- lh-20201231_htm                     XML   4.80M 
113: EXCEL       IDEA Workbook of Financial Reports                  XLSX    192K  
18: EX-101.CAL  XBRL Calculations -- lh-20201231_cal                 XML    275K 
19: EX-101.DEF  XBRL Definitions -- lh-20201231_def                  XML   1.80M 
20: EX-101.LAB  XBRL Labels -- lh-20201231_lab                       XML   3.13M 
21: EX-101.PRE  XBRL Presentations -- lh-20201231_pre                XML   2.27M 
17: EX-101.SCH  XBRL Schema -- lh-20201231                           XSD    271K 
115: JSON        XBRL Instance as JSON Data -- MetaLinks              651±   976K  
116: ZIP         XBRL Zipped Folder -- 0000920148-21-000018-xbrl      Zip    863K  


‘EX-24.7’   —   Power of Attorney


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  


Exhibit 24.7


POWER OF ATTORNEY

KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for the year ended December 31, 2020, under the Securities Exchange Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the Form 10-K in the name and on behalf of the Corporation or on behalf of the undersigned as a director or officer of the Corporation, and any amendments to the Form 10-K and any instrument, contract, document or other writing, of or in connection with the Form 10-K or amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, including this power of attorney, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, each acting alone, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has signed these presents in this 25th day of February, 2021.

By:/s/ RICHELLE P. PARHAM
Richelle P. Parham




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/25/21
For Period end:12/31/20SD
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/26/24  Lab Corp. of America Holdings     10-K       12/31/23  122:18M
 2/28/23  Lab Corp. of America Holdings     10-K       12/31/22  116:20M
 2/25/22  Lab Corp. of America Holdings     10-K       12/31/21  113:18M
 5/14/21  Lab Corp. of America Holdings     424B5       5/13/21    1:643K                                   Donnelley … Solutions/FA
 5/12/21  Lab Corp. of America Holdings     424B5                  1:631K                                   Donnelley … Solutions/FA


23 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/05/20  Lab Corp. of America Holdings     8-K:4,9    11/02/20   11:147K                                   Donnelley … Solutions/FA
 7/31/20  Lab Corp. of America Holdings     10-Q        6/30/20   80:12M
 5/08/20  Lab Corp. of America Holdings     10-Q        3/31/20   78:73M
11/25/19  Lab Corp. of America Holdings     8-K:1,9    11/25/19   12:504K                                   Donnelley … Solutions/FA
 6/05/19  Lab Corp. of America Holdings     8-K:5,7,9   6/04/19    3:314K                                   Donnelley … Solutions/FA
 6/03/19  Lab Corp. of America Holdings     8-K:1,2,7,9 6/03/19    4:647K                                   Donnelley … Solutions/FA
11/02/17  Lab Corp. of America Holdings     10-Q        9/30/17   74:10M
 8/22/17  Lab Corp. of America Holdings     8-K:1,8,9   8/22/17    5:516K                                   Donnelley … Solutions/FA
 5/16/16  Lab Corp. of America Holdings     8-K:5,9     5/11/16    3:313K                                   Donnelley … Solutions/FA
 1/30/15  Lab Corp. of America Holdings     8-K:1,8,9   1/30/15    7:815K                                   Donnelley … Solutions/FA
11/01/13  Lab Corp. of America Holdings     8-K:1,8,9  10/29/13    5:480K                                   Donnelley … Solutions/FA
 8/23/12  Lab Corp. of America Holdings     8-K:1,8,9   8/20/12    5:523K                                   Donnelley … Solutions/FA
 5/02/12  Lab Corp. of America Holdings     8-K:5,9     5/01/12    3:331K
11/19/10  Lab Corp. of America Holdings     8-K:1,8,9  11/16/10    6:1.2M
 5/07/08  Lab Corp. of America Holdings     8-K:5,9     5/07/08    2:14K
 3/25/08  Lab Corp. of America Holdings     DEF 14A     5/07/08    1:1.2M                                   Donnelley … Solutions/FA
 2/26/08  Lab Corp. of America Holdings     10-K        2/26/08   17:1.3M
 2/27/07  Lab Corp. of America Holdings     10-K       12/31/06   17:1.2M                                   Edgar Ease Svc Bureau/FA
 8/08/05  Lab Corp. of America Holdings     10-Q        8/08/05    8:511K
 3/03/05  Lab Corp. of America Holdings     10-K        3/03/05   17:1.4M
11/01/04  Lab Corp. of America Holdings     10-Q       11/01/04    6:486K
 3/18/02  Lab Corp. of America Holdings     10-K       12/31/01    7:582K
10/19/01  Lab Corp. of America Holdings     S-3                    8:538K                                   Davis Polk & … LLP 01/FA
Top
Filing Submission 0000920148-21-000018   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 7:41:39.3am ET